Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents

References

• Gould IM, MacKenzie FM. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. J. Appl. Microbiol. 92(Suppl.), S78–S84 (2002).
   Google Scholar
• Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab. Med. 24(2), 477–502 (2004).
   PubMed Web of Science ®Google Scholar
• Preston SL. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations. Ann. Pharmacother. 38(9 Suppl.), S14–S18 (2004).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Role of pharmacokinetics and pharmacodynamics: does the dose matter? Clin. Infect. Dis. 33(Suppl. 3), S238–S230 (2001).
   Google Scholar
• Vinks AA. The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int. J. Antimicrob. Agents. 19, 313–322 (2002).
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Barrett JS, Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J. Clin. Pharmacol. 40(9), 908–917 (2000).
   PubMed Web of Science ®Google Scholar
• Derendorf H, Lesko LJ, Chaikin P et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J. Clin. Pharmacol. 40(12 Pt 2), 1399–1418 (2000).
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16(2), 176–185 (1999).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents. 19(4), 355–358 (2002).
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Approved Standard M7–A6: Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically. Sixth Edition. Wayne, PA, USA (2003).
   Google Scholar
• Delacher S, Derendorf H, Hollenstein U et al. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J. Antimicrob. Chemother. 46(5), 733–739 (2000).
   PubMed Web of Science ®Google Scholar
• Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill-curve versus MIC. Antimicrob. Agents Chemother. 48(2), 369–377 (2004).
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel Dekker, NY, USA, 1–22 (2002).
   Google Scholar
• Kim MK, Nicolau DP. Aminoglycoside pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel-Dekker, NY, USA, 125–153 (2002).
   Google Scholar
• Owens Jr RC, Ambrose PG. Pharmacodynamics of quinolones. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel Dekker, NY, USA, 155–176 (2002).
   Google Scholar
• McNabb JJ, Bui KQ. β-lactam pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel-Dekker, NY, USA (2002).
   Google Scholar
• Nightingale CH, Matteos HM. Macrolide, azalide, and ketolide pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds), Marcel-Dekker, NY, USA (2002).
   Google Scholar
• Cunha BA, Matteos HM. Tetracycline pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale CH, Marakawa T, Ambrose PG (Eds), Marcel-Dekker, NY, USA (2002).
   Google Scholar
• Ross GH, Wright DH, Rotschafer JC, Ibrahim KH. Glycopeptide pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds), Marcel-Dekker, NY, USA (2002).
   Google Scholar
• Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int. J. Antimicrob. Agents. 23, 291–295 (2004).
   PubMed Web of Science ®Google Scholar
• Buijk SE, Gyssen IC, Mouton JW et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J. Antimicrob. Chemother. 49, 121–128 (2002).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Hoffman-Schmitt A, Shapiro S, Nashed N, Nieko CP. Use of Monte Carlo simulations to select therapeutic doses provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48(5), 1713–1718 (2004).
   PubMed Web of Science ®Google Scholar
• Sanchez-Navarro A, Colino CI, Sanchez-Recio MM. A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of clinical efficacy of ceftazidime. Clin. Pharmacokinet. 40, 124–134 (2001).
   Google Scholar
• Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints ready for primetime. Curr. Opin. Microbiol. 3, 515–521 (2000).
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother. 9, 292–296 (2003).
   PubMed Web of Science ®Google Scholar
• Griffith D, Dudley MN. Pharmacodynamics of RWJ-333441 (MC-04,546) when administered as the l-aspartyl prodrug RWJ-333442 against S. aureus in the neutropenic mouse thigh model. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Toronto, CA, USA (2000).
   Google Scholar
• Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22(4), 203–221 (2003).
   PubMed Web of Science ®Google Scholar
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48(1), 63–68 (2004).
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafzinger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumoniae caused by gram-negative bacteria. Antimicrob. Agents Chemother. 43, 623–629 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualization. Clin. Pharmacokinet. 37(4), 289–304 (1999).
   PubMed Web of Science ®Google Scholar
• Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 2: human trials. Ann. Pharmacother. 37, 1478–1488 (2003).
   PubMed Web of Science ®Google Scholar
• Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part I: in vitro and animal models. Ann. Pharmacother. 37, 1287–1298 (2003).
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. Am. J. Health Syst. Pharm. 56(22 Suppl. 3), S21–S24 (1999).
   Web of Science ®Google Scholar
• Schentag JJ. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J. Chemother. 11(6), 426–439 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez-Recio MM, Colino CI, Sanchez-Navarro A. A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. J. Antimicrob. Chemother. 45(3), 321–328 (2000).
   PubMed Web of Science ®Google Scholar
• Dalhoff A. Pharmacodynamics of fluoroquinolones. J. Antimicrob. Chemother. 43(Suppl. B), 51–59 (1999).
   PubMed Web of Science ®Google Scholar
• Smith P, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin. Ther. 23(8), 1231–1244 (2001).
   PubMed Web of Science ®Google Scholar
• Cha R, Grucz Jr RG, Rybak MJ. Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob. Agents Chemother. 47(5), 1598–1603 (2003).
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37(5), 1073–1081 (1993).
   PubMed Web of Science ®Google Scholar
• Craig WA. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3), S233–S237 (2001).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones agaisnt Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45, 2793–2797 (2001).
   PubMed Web of Science ®Google Scholar
• Lacy ML, Lu W, Nicolau DP, Quintiliani R, Nightingale CH. Pharmacodynamic comparisons of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43, 79–86 (1999).
   Web of Science ®Google Scholar
• Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 43, 1118–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1), S39–S46 (2001).
   PubMedGoogle Scholar
• Amsden GW, Owens Jr RC, Bertino JS. AUIC in humans: a fact-based discussion. Clin. Infect. Dis. 37(10), 1518–1521 (2003).
   Google Scholar
• Brunner M, Stass H, Moller JG et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 46(12), 3724–3730 (2002).
   PubMed Web of Science ®Google Scholar
• de la Pena A, Dalla Costa T, Talton JD et al. Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm. Res. 18(9), 1310–1314 (2001).
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Derendorf H, Muller M. Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J. Clin. Pharmacol. 57(3), 211–219 (2001).
   PubMed Web of Science ®Google Scholar
• Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents. 19(4), 285–290 (2002).
   PubMed Web of Science ®Google Scholar
• Liu P. Pharmacokinetics and pharmacodynamics of cefpodoxime and cefixime. Department of Pharmaceutics. Doctoral thesis. Department of Pharmaceutics, University of Florida, FL, USA, 176 (2002).
   Google Scholar
• Liu Q. Pharmacokinetic and Pharmacodynamic Modeling of Antibiotics and Resistance. Department of Pharmaceutics. Doctoral thesis. University of Florida, FL, USA, 117 (2004).
   Google Scholar
• Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48(6), 2061–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Dudley MN, Griffith D. Animal models of infection for the study of antibiotic pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel-Dekker, NY, USA (2002).
   Google Scholar
• Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 19(4), 261–268 (2002).
   PubMed Web of Science ®Google Scholar
• Liu Q, Rand K, Derendorf H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int. J. Antimicrob. Agents. 23(5), 494–497 (2004).
   PubMed Web of Science ®Google Scholar
• Zinner SH, Firsov AA. In vitro dynamic model for determining the comparative pharmacology of fluoroquinolones. Am. J. Health Syst. Pharm. 56(22 Suppl. 3), S12–S15 (1999).
   PubMed Web of Science ®Google Scholar
• de la Pena A, Graebe A, Rand KH et al. PK-PD modeling of the effect of cefaclor on four different bacterial strains. Int. J. Antimicrob. Agents. 23, 218–225 (2004).
   PubMed Web of Science ®Google Scholar
• Nolting A, Dalla Costa T, Rand K, Derendorf H. Pharmacokinetic-pharmacodynamic modeling of the in vitro antibiotic effect of piperacillin in vitro. Pharm. Res. 13(1), 91–96 (1996).
   PubMed Web of Science ®Google Scholar
• Dalhoff A, MacGowan A, Cars O et al. Comparative evaluation of seven different in vitro pharmacodynamic models of infection. 43rd Interscience Conference of Antimicrobial Agents Chemotherapy. American Society for Microbiology. Chicago, IL, USA (2003).
   Google Scholar
• Schuck EL, Dalhoff A, Stass H, Derendorf H. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in a modified release (MR) dosage form. Infection (2005) (In Press).
   PubMedGoogle Scholar
• Schuck EL, Dalhoff A, Stass H, Derendorf H. Modeling the biphasic killing kinetics of quinolones. 2004 American Association of Pharmaceutical Scientists Annual Meeting and Exposition. AAPS, Salt Lake City, UT, USA (2003).
   Google Scholar
• MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens. J. Antimicrob. Chemother. 46, 163–170 (2000).
   PubMed Web of Science ®Google Scholar
• Rybak M, Allen GP, Hershberger E. In vitro antibiotic pharmacodynamics models. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose P (Eds). Marcel-Dekker, NY, USA 41–65 (2002).
   Google Scholar
• Khunvichai A. Pharmacokinetics and Pharmacodynamics of Faropenem Daloxate. Doctoral thesis. Department of Pharmaceutics, University of Florida, Gainesville, USA, 157 (2003).
   Google Scholar
• Carret G, Flandrois JP, Lobry JR. Biphasic kinetics of bacterial killing by quinolones. J. Antimicrob. Chemother. 27, 319–327 (1991).
   PubMed Web of Science ®Google Scholar
• Rapp RP, Campion JJ. Challenges in pharmacodynamic studies of antimicrobial resistance. Ann. Pharmacother. 37, 1329–1330 (2003).
   PubMed Web of Science ®Google Scholar
• Campion JJ, Evans M, McNamara P. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. AAPS Annual Meeting and Exposition. Toronto, Canada (2002).
   Google Scholar
• Muller M, Brenner M, Hollenstein U et al. Tissue penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patient. Antimicrob. Agents Chemother. 43, 2056–2058 (1999).
   PubMed Web of Science ®Google Scholar
• Müller M, Eichler H-G. Tissue pharmacokinetics during early clinical drug development. Applied clinical trials. 45(5), 56–60 (1999).
   Google Scholar
• Firsov AA, Zinner SH, Lubenko IY, Portnoy YA, Vostrov SN. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy 48(6), 275–279 (2002).
   PubMed Web of Science ®Google Scholar
• Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J. Antimicrob. Chemother. 50(4), 533–539 (2002).
   PubMed Web of Science ®Google Scholar
• Firsov AA, Lubenko IY, Portnoy YA, Zinner SH, Vostrov SN. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob. Agents Chemother. 45(3), 927–931 (2001).
   PubMed Web of Science ®Google Scholar
• Trujillo M, Correa N, Olsen K et al. Cefprozil concentrations in middle ear fluid of children with acute otitis media. Pedriatr. Infect. Dis. J. 19(3), 268–269 (2000).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diag. Microbiol. Infect. Dis. 38, 151–157 (2000).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY antimicrobial surveillance program. Clin. Microbiol. Infect. 10(7), 645–651 (2004).
   PubMed Web of Science ®Google Scholar
• Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acetinobacter baumanii, and Pseudomonas aeruginosa. Pharmacotherapy 24(1), 8–15 (2004).
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Hardalo C et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45(1), 13–22 (2001).
   PubMed Web of Science ®Google Scholar
• Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47(6), 1853–1861 (2003).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J. Antimicrob. Chemother. 52, 435–440 (2003).
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of β-lactams may account for the therapeutic failure in patients with septic shock. Crit. Care Med. 29(2), 385–391 (2001).
   PubMed Web of Science ®Google Scholar